Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development

TheFly reported connected January 27 that Barclays initiated sum of ALT with an Overweight standing and a $20 terms target. Strong underlying fundamentals, continuous merger and acquisition activity, and alleviating medicine pricing concerns are the reasons down the firm’s optimistic outlook for the biotech manufacture successful 2026. Additionally, Barclays pointed retired that ALT and different biotech stocks are inactive inexpensive successful examination to their pipeline potential.

Altimmune, Inc. (NASDAQ:ALT) besides announced connected the aforesaid time that it intends to usage the nett proceeds from the offering for moving capital, wide institution needs, and getting acceptable for its adjacent Phase 3 MASH research. The FDA’s Breakthrough Therapy Designation and affirmative Phase 2b 48-week findings bolster the company’s assertion that pemvidutide is simply a caller glucagon/GLP-1 dual agonist.

Altimmune, Inc. (NASDAQ:ALT) is simply a clinical-stage biopharmaceutical institution processing next-generation peptide-based therapeutics for metabolic and liver diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its pb candidate, pemvidutide, targets GLP-1 and glucagon receptors to trim weight, liver fat, and cardiometabolic risk.

While we admit the imaginable of ALT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.